PMID- 28852153
OWN - NLM
STAT- MEDLINE
DCOM- 20190423
LR  - 20231112
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Aug 29
TI  - Ethyl Acetate Extract Components of Bushen-Yizhi Formula Provides Neuroprotection 
      against Scopolamine-induced Cognitive Impairment.
PG  - 9824
LID - 10.1038/s41598-017-10437-4 [doi]
LID - 9824
AB  - Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder and there 
      is no effective cure for this devastating disease to date. Bushen Yizhi Formula 
      (BSYZ-F), a Chinese herbal compound, has proved to be effective for AD. In this 
      study, we further investigate the effective part of BSYZ-F, ethyl acetate extract 
      components of BSYZ-F (BSYZ-E), protects scopolamine (SCOP)-induced cognitive 
      impairment, which shows a similar effect to BSYZ-F. We also find that BSYZ-E 
      could protect against SCOP-induced cholinergic system dysfunction. In neuron 
      function level, BSYZ-E remarkably elevates protein levels of nerve growth factor 
      (NGF) and brain-derived neurotrophic factor (BDNF). BSYZ-E also significantly 
      mitigates SCOP-induced apoptosis, oxidative stress and nitrosative stress. 
      Conclusively, BSYZ-E, the effective part of BSYZ-F, can provide neuroprotection 
      against SCOP-induced cognitive impairment through a multifunctional strategy. 
      These findings suggest that BSYZ-E might be developed as a therapeutic drug for 
      AD by targeting multiple pathways of the pathogenesis.
FAU - Zhang, Shi-Jie
AU  - Zhang SJ
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Luo, Dan
AU  - Luo D
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Li, Lin
AU  - Li L
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Tan, Rui-Rong
AU  - Tan RR
AD  - International Center for Translational Chinese Medicine, Sichuan Academy of 
      Chinese Medicine Sciences, Chengdu, China.
FAU - Xu, Qing-Qing
AU  - Xu QQ
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Qin, Jie
AU  - Qin J
AD  - Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Zhu, Lei
AU  - Zhu L
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Luo, Na-Chuan
AU  - Luo NC
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Xu, Ting-Ting
AU  - Xu TT
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Zhang, Rong
AU  - Zhang R
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Yang, Lei
AU  - Yang L
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China. yanglei@gzucm.edu.cn.
FAU - Wang, Qi
AU  - Wang Q
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, China. wangqi@gzucm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170829
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (bushen yizhi)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - DL48G20X8X (Scopolamine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
SB  - IM
EIN - Sci Rep. 2020 Jan 15;10(1):744. PMID: 31937843
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Biomarkers
MH  - Brain/drug effects/metabolism
MH  - Cognitive Dysfunction/drug therapy/*etiology/metabolism/*psychology
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/chemistry/*pharmacology
MH  - Immunohistochemistry
MH  - Maze Learning/drug effects
MH  - Memory/drug effects
MH  - Mice
MH  - Neurons/drug effects/metabolism
MH  - Neuroprotective Agents/chemistry/*pharmacology
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Oxidative Stress/drug effects
MH  - Scopolamine/*adverse effects
PMC - PMC5575143
COIS- The authors declare that they have no competing interests.
EDAT- 2017/08/31 06:00
MHDA- 2019/04/24 06:00
PMCR- 2017/08/29
CRDT- 2017/08/31 06:00
PHST- 2017/01/09 00:00 [received]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2017/08/31 06:00 [entrez]
PHST- 2017/08/31 06:00 [pubmed]
PHST- 2019/04/24 06:00 [medline]
PHST- 2017/08/29 00:00 [pmc-release]
AID - 10.1038/s41598-017-10437-4 [pii]
AID - 10437 [pii]
AID - 10.1038/s41598-017-10437-4 [doi]
PST - epublish
SO  - Sci Rep. 2017 Aug 29;7(1):9824. doi: 10.1038/s41598-017-10437-4.